Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study
China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...
Clinical trial approval / initiation
Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...
Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485
China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...
Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...
Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...
HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study
On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...
Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828
German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Guangdong Zhongsheng Completes Enrollment for RAY1216 Phase III Study in COVID-19
China – based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the completion of...
Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy
Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...
CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study
China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...
BrightGene Receives NMPA Approval for BGM0504 Clinical Trial
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...
Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...
Simcere Receives NMPA Clearance for SIM0237 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...